Advances in the Treatment of RET Fusion-positive Advanced Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2021.101.43
- Author:
Qingyun GAO
1
;
Junwei SU
1
;
Faman XIAO
1
;
Xiaocheng LIN
1
;
Jinji YANG
1
Author Information
1. Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangzhou 510080, China.
- Publication Type:Review
- Keywords:
Lung neoplasms;
RET fusion;
Targeted therapy
- MeSH:
Carcinoma, Non-Small-Cell Lung/genetics*;
Humans;
Lung Neoplasms/genetics*;
Mutation;
Protein Kinase Inhibitors/therapeutic use*;
Proto-Oncogene Proteins c-ret/genetics*
- From:
Chinese Journal of Lung Cancer
2021;24(12):853-861
- CountryChina
- Language:Chinese
-
Abstract:
Rearranged during transfection (RET) fusions are found in 0.7% to 2% of non-small cell lung cancer (NSCLC). Fusions between RET gene and other domains represent the distinct biological and clinicopathological subtypes of NSCLC. Recent years have witnessed the remarkable advancement of RET fusion-positive advanced NSCLC therapy. Conventional chemotherapy produced moderate clinical benefits. Prior to the introduction of targeted therapy or in the context of unavailability, platinum-based systemic regimens are initial therapy options. Immunotherapy predicted minimal response in the presence of RET fusions while currently available data have been scarce, and the single-agent immunotherapy or in combination with chemotherapy regimens are not recommended as initial systemic therapy in this population. The repurpose of multi-target kinase inhibitors in patients with RET fusion-positive NSCLC showed encouraging therapeutic activity, with only cabozantinib and vandetanib being recommended as initial or subsequent options under certain circumstances. However, there are still unmet clinical needs. Pralsetinib and selpercatinib have been developed as tyrosine kinase inhibitors (TKI) selectively targeting RET variation of fusions or mutations, and both agents significantly improved the prognosis of patients with RET fusion-positive NSCLC. Pralsetinib and selpercatinib have been established as preferred first-line therapy or subsequent therapy options. As observed with other TKIs treatment, resistance has also been associated with RET targeted inhibition, and the acquired resistance eventually affect the long-term therapeutic effectiveness, leading to limited subsequent treatment options. Therefore, it is essential to identify resistance mechanisms to TKI in RET fusion-positive advanced NSCLC to help reveal and establish new strategies to overcome resistance. Here, we review the advances in the treatment of RET fusion-positive advanced NSCLC.
.
